{"generic":"Pancrelipase","drugs":["Creon","Palcaps","Pancreaze","Pancrelipase","Pancrelipase","Pangestyme EC","Panocaps","Ultracaps","Zenpep"],"mono":{"0":{"id":"me4s0","title":"Generic Names","mono":"Pancrelipase"},"1":{"id":"me4s1","title":"Dosing and Indications","sub":[{"id":"me4s1b4","title":"Adult Dosing","mono":"<ul><li>different brands of pancrelipase are not interchangeable with each other; FDA-approved pancreatic enzyme products include Creon(R), Zenpep(R), Pancreaze(R), Pertzye(TM), Ultresa(TM), and Viokace(TM)<\/li><li><b>Exocrine pancreatic insufficiency, Due to chronic pancreatitis or pancreatectomy:<\/b> Creon(R), 72,000 lipase units\/meal for at least 100 grams of fat consumption\/day; usually, half the mealtime dose is given with a snack<\/li><li><b>Exocrine pancreatic insufficiency, Due to chronic pancreatitis or pancreatectomy:<\/b> Viokace(TM) in combination with a proton pump inhibitor, initial, 500 lipase units\/kg\/meal ORALLY; MAX of 2500 lipase units\/kg\/meal (or less than or equal to 10,000 lipase units\/kg\/day), or less than 4000 lipase units\/g fat ingested\/day; usually, half the mealtime dose is given with a snack<\/li><li><b>Pancreatic insufficiency, Cystic fibrosis or other conditions:<\/b> dose should be individualized based on clinical symptoms, degree of steatorrhea present, and fat content of diet<\/li><li><b>Pancreatic insufficiency, Cystic fibrosis or other conditions:<\/b> initial, 500 lipase units\/kg\/meal ORALLY; titrate up to a MAX of 2500 lipase units\/kg\/meal (or less than or equal to 10,000 lipase units\/kg\/day), or less than 4000 lipase units\/g fat ingested\/day; usually, half the mealtime dose is given with a snack<\/li><\/ul>"},{"id":"me4s1b5","title":"Pediatric Dosing","mono":"<ul><li>different brands of pancrelipase are not interchangeable with each other; FDA-approved pediatric pancreatic enzyme products include Creon(R), Zenpep(R), Pancreaze(R), Pertzye(TM), Ultresa(TM); safety and effectiveness of Viokace(TM) have not been established in pediatric patients<\/li><li>use of products is limited by available dosage strengths; dividing capsule contents is not recommended<\/li><li><b>Pancreatic insufficiency, Cystic fibrosis or other conditions:<\/b> dose should be individualized based on clinical symptoms, degree of steatorrhea present, and fat content of diet<\/li><li><b>Pancreatic insufficiency, Cystic fibrosis or other conditions:<\/b> (infants up to 12 months) 2600 lipase units ORALLY per 120 mL of formula or per breastfeeding (Pancreaze[R])<\/li><li><b>Pancreatic insufficiency, Cystic fibrosis or other conditions:<\/b> (infants up to 12 months) 3000 lipase units ORALLY per 120 mL of formula or per breastfeeding (Zenpep[R], Creon[R])<\/li><li><b>Pancreatic insufficiency, Cystic fibrosis or other conditions:<\/b> (children older than 12 months and younger than 4 years) initial, 1000 lipase units\/kg\/meal ORALLY; titrate up to a MAX of 2500 lipase units\/kg\/meal (or less than or equal to 10,000 lipase units\/kg\/day), or less than 4000 lipase units\/g fat ingested\/day; usually, half the mealtime dose is given with a snack<\/li><li><b>Pancreatic insufficiency, Cystic fibrosis or other conditions:<\/b> (children 4 years or older) initial, 500 lipase units\/kg\/meal ORALLY; titrate up to a MAX of 2500 units\/kg\/meal (or less than or equal to 10,000 units\/kg\/day), or less than 4000 units\/g fat ingested\/day; usually, half the mealtime dose is given with a snack<\/li><\/ul>"},{"id":"me4s1b6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> decrease doses expressed as lipase units\/kg\/meal since the elderly weigh more but tend to ingest less fat\/kg "},{"id":"me4s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Exocrine pancreatic insufficiency, Due to chronic pancreatitis or pancreatectomy<\/li><li>Pancreatic insufficiency, Cystic fibrosis or other conditions<\/li><\/ul>"}]},"3":{"id":"me4s3","title":"Contraindications\/Warnings","sub":[{"id":"me4s3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"me4s3b10","title":"Precautions","mono":"<ul><li>allergy to porcine proteins; severe allergic reactions (anaphylaxis, asthma, hives, and pruritus) have been rarely reported with pancrelipase products; increased risk of elevated blood uric acid levels<\/li><li>doses greater than 6000 lipase units\/kg of body weight\/meal; not recommended; dose reductions recommended<\/li><li>fibrosing colonopathy, new-onset or worsening, (including progression to stricture formation) has been rarely reported, typically in association with prolonged use of high doses in pediatric patients; doses greater than 6000 lipase units\/kg\/meal are not recommended; monitoring recommended<\/li><li>gout; purines may increase blood uric acid levels<\/li><li>hyperuricemia; purines may increase blood uric acid levels<\/li><li>inability to swallow; risk for oral mucosa irritation if drug is retained in mouth<\/li><li>lactose intolerance; tablets contain lactose monohydrate (tablets)<\/li><li>pediatric patients with doses greater than 6000 lipase units\/kg of body weight\/meal; increased risk of colonic stricture<\/li><li>porcine-derived product; theoretical risk of infectious viral disease transmittal<\/li><li>renal impairment; purines may increase blood uric acid levels<\/li><li>report suspected adverse reactions to the United States Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"me4s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"me4s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"me4s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (up to 10%), Indigestion (10%)<\/li><li><b>Musculoskeletal:<\/b>Neck pain (pediatrics, 14%)<\/li><li><b>Respiratory:<\/b>Cough (6% to 10%), Nasal congestion (pediatrics, 14%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Distal intestinal obstruction syndrome, Fibrosing colonopathy (Rare), Stricture of colon (Rare)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction, Lymphadenopathy (pediatrics, 11%)<\/li><li><b>Other:<\/b>Recurrent tumor, Carcinoma<\/li><\/ul>"},"6":{"id":"me4s6","title":"Drug Name Info","sub":[{"id":"me4s6b17","title":"US Trade Names","mono":"<ul><li>Creon<\/li><li>Pancreaze<\/li><li>Zenpep<\/li><li>Pangestyme EC<\/li><li>Ultracaps<\/li><li>Pancrelipase<\/li><li>Palcaps<\/li><li>Panocaps<\/li><\/ul>"},{"id":"me4s6b18","title":"Synonyms","mono":"<ul><li>Enzymes<\/li><li>Enzymes, Multi<\/li><li>Enzyme<\/li><\/ul>"},{"id":"me4s6b19","title":"Class","mono":"<ul><li>Digestant<\/li><li>Enzyme<\/li><li>Enzyme Replacement<\/li><li>Gastrointestinal Agent<\/li><\/ul>"},{"id":"me4s6b20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},{"id":"me4s6b21","title":"Generic Availability","mono":"Yes<br\/>"}]},"7":{"id":"me4s7","title":"Mechanism Of Action","mono":"Acting as a replacement for digestive enzymes secreted by the pancreas, the porcine derived proteolytic, amylolytic, and lipolytic enzymes in pancrelipase enhance the digestion of proteins, starches, and fats in the duodenum and proximal small intestines.<br\/>"},"8":{"id":"me4s8","title":"Pharmacokinetics","sub":[{"id":"me4s8b23","title":"Absorption","mono":"Bioavailability: negligible <br\/>"}]},"9":{"id":"me4s9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>for infants up to 12 months, administer immediately prior to feeding; do not mix pancrelipase capsule contents directly into formula or breast milk, may decrease efficacy<\/li><li>take with meals and snacks, with sufficient fluid<\/li><li>swallow capsule or tablet whole, do not crush or chew, may irritate oral mucosa<\/li><li>Viokace(TM) is not enteric-coated; the tablets should be taken in combination with a proton pump inhibitor<\/li><li>for patients having difficulty swallowing, capsules may be opened and added to a small quantity of acidic soft food, dispersed equally, swallowed immediately and followed by sufficient fluid<\/li><li>do not divide the Ultresa(TM) or Pertzye(TM) capsule contents in small fractions to deliver small doses of lipase; Ultresa(TM) and Pertzye(TM) use in children is limited by the available capsule dosage strengths and their ability to provide the recommended dose based on age and weight<\/li><li>discard any unused portion of capsule contents<\/li><\/ul>"},"10":{"id":"me4s10","title":"Monitoring","mono":"<ul><li>decrease in the frequency of greasy stools (ie, steatorrhea), improvement in food digestion, and a decrease in mean coefficient of fat absorption (CFA) are indicative of efficacy<\/li><li>uric acid levels in patients with hyperuricemia, gout, or renal impairment<\/li><li>signs\/symptoms of progression to colon stricture formation from fibrosing colonopathy; especially with higher doses, with prolonged use, and in pediatric cystic fibrosis patients<\/li><\/ul>"},"11":{"id":"me4s11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: (Amylase - Lipase - Protease) 60000 U-4800 U-60000 U<br\/><\/li><li><b>Creon<\/b><br\/>Oral Capsule, Delayed Release: (Amylase - Lipase - Protease) 15000 U-3000 U-9500 U, 30000 U-6000 U-19000 U, 60000 U-12000 U-38000 U, 120000 U-24000 U-76000 U, 180000 U-36000 U-114000 U<br\/><\/li><li><b>Dygase<\/b><br\/>Oral Capsule: (Amylase - Lipase - Protease) 30000 U-2400 U-30000 U<br\/><\/li><li><b>Pancreaze<\/b><br\/>Oral Capsule, Delayed Release: (Amylase - Lipase - Protease) 17500 U-4200 U-10000 U, 43750 U-10500 U-25000 U, 61000 U-21000 U-37000 U, 70000 U-16800 U-40000 U<br\/><\/li><li><b>Pancrelipase<\/b><br\/><ul><li>Oral Capsule, Delayed Release: (Amylase - Lipase - Protease) 27000 U-5000 U-17000 U<\/li><li>Oral Tablet: (Amylase - Lipase - Protease) 30000 U-8000 U-30000 U<\/li><\/ul><\/li><li><b>Pangestyme EC<\/b><br\/>Oral Capsule, Delayed Release: (Amylase - Lipase - Protease) 20000 U-4500 U-25000 U<br\/><\/li><li><b>Pertzye<\/b><br\/>Oral Capsule, Delayed Release: (Amylase - Lipase - Protease) 30250 U-8000 U-28750 U, 60500 U-16000 U-57500 U<br\/><\/li><li><b>Ultresa<\/b><br\/>Oral Capsule, Delayed Release: (Amylase - Lipase - Protease) 27600 U-13800 U-27600 U, 41400 U-20700 U-41400 U, 46000 U-23000 U-46000 U<br\/><\/li><li><b>Viokace<\/b><br\/>Oral Tablet: (Amylase - Lipase - Protease) 39150 U-10440 U-39150 U, 78300 U-20880 U-78300 U<br\/><\/li><li><b>Zenpep<\/b><br\/>Oral Capsule, Delayed Release: (Amylase - Lipase - Protease) 16000 U-3000 U-10000 U, 27000 U-5000 U-17000 U, 55000 U-10000 U-34000 U, 82000 U-15000 U-51000 U, 105000 U-25000 U-79000 U, 109000 U-20000 U-68000 U, 218000 U-40000 U-136000 U<br\/><\/li><\/ul>"},"13":{"id":"me4s13","title":"Clinical Teaching","mono":"<ul><li>Advise patient of the theoretical risk of infectious viral disease transmittal with porcine-derived pancreatic enzyme products.<\/li><li>Drug may cause headache, dizziness, cough, diarrhea, flatulence, abdominal pain, throat pain, nose bleeds, anal pruritus, or biliary tract stones.<\/li><li>Tell patient to immediately report signs\/symptoms of allergic reaction or fibrosing colonopathy including abdominal pain, bloating, nausea, vomiting, or diarrhea<\/li><li>Advise patient not to exceed 10,000 lipase units\/kg of body weight\/day without prior physician approval.<\/li><li>Patient should always take this drug with food  and an adequate amount of water. Do not chew or crush.<\/li><li>If patient is unable to swallow the capsule whole, instruct patient to sprinkle the contents of the capsule onto a small amount of soft, acidic food (eg, room temperature applesauce), swallow without chewing, and follow with juice or water.<\/li><li>In the event of a missed dose, counsel patient that next dose should be taken with the next meal or snack. Do not take a double dose.<\/li><\/ul>"}}}